IL18 and COVID-19: Because circulating IL-18 and IL-1β are elevated in severe COVID-19 (7, 10), and SARS-CoV-2 exposure leads to the release of these inflammasome-associated cytokines in macrophages, the inflammasome may be a therapeutic target during the inflammatory phase of the disease.